Main Article Content
Abstract
The context investigates the therapeutic potential of Caryota urens, a species rich in diverse phytochemical constituents, for the management of liver diseases. Liver diseases (LD) constitute a significant global health burden, accounting for nearly 2 million deaths annually worldwide. Major etiological factors include chronic viral infections such as hepatitis B (HBV) and hepatitis C (HCV), alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), as well as autoimmune and genetic disorders. This study highlights the bioactive profile of Caryota urens, encompassing polyphenols, flavonoids, amino acids, and other metabolites, which possess potent antioxidant and anti-inflammatory properties capable of modulating key mechanisms involved in liver disease pathophysiology. The document further provides an overview of the epidemiology, pathophysiology, risk factors, and progressive clinical stages of liver disease. Current therapeutic approaches primarily emphasize symptomatic relief rather than targeting the underlying disease mechanisms. In this context, Caryota urens emerges as a promising natural candidate for the development of novel hepatoprotective therapies. The findings emphasize the necessity for further in-depth investigations to validate the efficacy and safety of its bioactive compounds in liver disease management.